__timestamp | AstraZeneca PLC | Genmab A/S |
---|---|---|
Wednesday, January 1, 2014 | 26095000000 | 850385000 |
Thursday, January 1, 2015 | 24708000000 | 1133041000 |
Friday, January 1, 2016 | 23002000000 | 1816122000 |
Sunday, January 1, 2017 | 22465000000 | 2365436000 |
Monday, January 1, 2018 | 22090000000 | 3025137000 |
Tuesday, January 1, 2019 | 24384000000 | 5366000000 |
Wednesday, January 1, 2020 | 26617000000 | 10111000000 |
Friday, January 1, 2021 | 37417000000 | 8482000000 |
Saturday, January 1, 2022 | 44351000000 | 14595000000 |
Sunday, January 1, 2023 | 45811000000 | 16474000000 |
Unleashing insights
In the ever-evolving pharmaceutical industry, AstraZeneca PLC and Genmab A/S have demonstrated remarkable revenue trajectories over the past decade. From 2014 to 2023, AstraZeneca's revenue surged by approximately 75%, reaching its peak in 2023. This growth reflects the company's strategic focus on innovation and expansion in emerging markets. Meanwhile, Genmab A/S, a leader in antibody therapeutics, experienced an impressive revenue increase of nearly 1,800% during the same period, underscoring its successful product pipeline and strategic partnerships.
These trends highlight the dynamic nature of the pharmaceutical sector, where innovation and strategic alliances drive success.
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Annual Comparison of SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline
5 Year Trend in Average Market Capitalization for AbbVie
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Number of Employees for Top 10 Healthcare Companies
Number of Employees for Top 10 Pharma Companies
Average Market Capitalization of Abbvie Annually
5 Year Trend in Market Capitalization for AbbVie
5 Year Trend in Average Market Capitalization for AbbVie
Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters